OCULAR THERAPEUTIX, INC Income Statement
OCUL / Health Care|14 years of annual SEC 10-K data (FY2012-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 14 fiscal years. All figures from audited SEC 10-K filings.
OCULAR THERAPEUTIX, INC reported $52M in revenue and $266M in net loss for FY2025. Revenue has grown at a 93.1% compound annual rate over the past 13 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.0M | $63.7M | $58.4M | $17.4M | $4.2M | $4.2M | $1.9M | $2.0M | $1.9M | $1.9M | $772.0K | $10.0K | - | $10.0K |
| Cost of Revenue | $6.6M | $5.6M | $5.3M | $2.1M | $2.3M | $2.3M | $457.0K | $465.0K | $457.0K | $443.0K | $91.0K | $7.0K | - | $7.0K |
| SG&A Expense | $64.4M | $60.7M | $33.9M | $22.9M | $22.1M | $22.1M | $15.5M | $18.8M | $15.5M | $11.0M | $1.8M | $1.5M | $1.8M | $1.5M |
| R&D Expense | $197.1M | $127.6M | $61.1M | $28.7M | $41.1M | $41.1M | $30.9M | $36.9M | $30.9M | $27.1M | $10.5M | $11.5M | $10.5M | $11.5M |
| Operating Income | -$270.0M | -$171.8M | -$82.4M | -$62.8M | -$85.8M | -$85.8M | -$61.9M | -$59.1M | -$61.9M | -$43.3M | -$12.9M | -$13.7M | -$12.9M | -$13.7M |
| Interest Expense | - | $887.0K | $11.3M | $6.8M | $6.1M | $6.1M | $1.9M | $1.7M | $1.9M | $1.7M | $441.0K | $377.0K | $441.0K | $377.0K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$265.9M | -$193.5M | -$80.7M | -$155.6M | -$86.4M | -$86.4M | -$63.4M | -$60.0M | -$63.4M | -$44.7M | -$13.3M | -$14.1M | -$13.3M | -$14.1M |
| EPS (Basic) | -$1.01 | -$0.92 | -$0.09 | -$2.56 | -$1.91 | - | -$0.41 | - | - | - | - | - | - | - |
| EPS (Diluted) | -$1.02 | -$0.97 | -$0.98 | -$2.56 | -$1.91 | -$1.91 | -$0.45 | -$1.80 | -$1.71 | -$2.69 | -$5.11 | -$5.60 | - | - |
| Shares Outstanding | 157.7M | 115.0M | 77.2M | 76.7M | 76.0M | 50.3M | 41.5M | 29.7M | 25.0M | 24.8M | 21.3M | 2.7M | 2.6M | 2.5M |
| Operating Margin | -519.8% | -269.6% | -141.0% | -361.1% | -2029.9% | -2029.9% | -3220.1% | -2970.8% | -3220.1% | -2296.0% | -1671.4% | -136710.0% | - | - |
| Profit Margin | -511.9% | -303.7% | -138.1% | -894.3% | -2043.3% | -2043.3% | -3296.2% | -3014.0% | -3296.2% | -2369.0% | -1725.0% | -140930.0% | - | - |